TME Pharma Extends Debt Maturity to Enhance Financial Visibility

TME Pharma N.V. has announced the extension of its outstanding debt maturity by 13 months, now due on June 30, 2028. This move extends the company's financial visibility until the second quarter of 2028. The decision involves all existing debtholders, including the CEO and two members of the Supervisory Board. In addition, TME Pharma is engaging in new bond financings to maintain financial stability.

The CEO, Diede van den Ouden, has played a crucial role by providing a new EUR 250,000 straight bond. Moreover, the company secured EUR 500,000 in bond financing from Hexagon Capital Fund. This funding strategy limits shareholder dilution while supporting long-term strategic goals.

This debt strategy supports ongoing licensing talks for NOX-A12, aiming to secure new revenue streams. The company's leadership remains focused on achieving sustained financial growth and shareholder value.